249764-16-7

Downstream Products

• 253329-83-8 {(S)-2-[5-(tert-Butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-phenyl]-1-[(1R,3S)-3-((R)-cyano-morpholin-4-yl-methyl)-8-hydroxy-5,7-dimethoxy-2,6-dimethyl-1,2,3,4-tetrahydro-isoquinolin-1-yl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 253329-78-1 (R)-{(1R,3S)-1-[(S)-1-Amino-2-(5-hydroxy-2,4-dimethoxy-3-methyl-phenyl)-ethyl]-8-hydroxy-5,7-dimethoxy-2,6-dimethyl-1,2,3,4-tetrahydro-isoquinolin-3-yl}-morpholin-4-yl-acetonitrile 
• 66082-27-7 Saframycin A 
• 429687-43-4 ((S)-2-[5-(tert-Butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-phenyl]-1-{[(E)-(1S,2R)-2-cyano-1-(5-hydroxy-2,4-dimethoxy-3-methyl-benzyl)-2-morpholin-4-yl-ethylimino]-methyl}-ethyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 

Relevant academic research and scientific papers

NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.